Published • loading... • Updated
Biogen to acquire RayThera for up to $1bn
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Verdict HospitalReposted by 
Pharmaceutical Business review
Pharmaceutical Business reviewBiogen to acquire RayThera for up to $1bn
Biogen is to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn.The post Biogen to acquire RayThera for up to $1bn appeared first on Hospital Management.
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
